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Abstract 
Objective: Bacteriophages (or phages) are viruses which infect and lyse bacteria. The therapeutic use of phages 
(phage therapy) has regained attention in the last decades as an alternative strategy to treat infections caused by 
antimicrobial‑resistant bacteria. In clinical settings it is most likely that phages are administered adjunct to antibiot‑
ics. For successful phage therapy it is therefore crucial to investigate different phage‑antibiotic combinations in vivo. 
This study aimed to elucidate the combinatorial effects of systemic daptomycin and nebulised bacteriophages for the 
treatment of experimental pneumonia due to methicillin‑resistant Staphylococcus aureus (MRSA).
Results: Using a rat model of ventilator‑associated pneumonia caused by MRSA, the simultaneous application of 
intravenous daptomycin and nebulised phages was not superior to aerophage therapy alone at improving animal 
survival (55% vs. 50%), or reducing bacterial burdens in the lungs, or spleen. Thus, this combination does not seem to 
be of benefit for use in patients with MRSA pneumonia.
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Introduction
Ventilator-associated pneumonia (VAP) is a frequent 
complication for mechanically ventilated patients in 
intensive care units [1]. The problem of VAP has been 
compounded by the spread of antibiotic-resistant bac-
terial strains that respond poorly to standard-of-care 
therapies. Alternative strategies for the treatment of 
VAP warrant investigation. In this context, the use of 
bacterial viruses (called bacteriophages or phages) for 
the treatment of pneumonia due to methicillin-resistant 
Staphylococcus aureus (MRSA) has been investigated 
using an experimental rat model designed to mimic VAP 
[2–4]. Phages were as effective as antibiotics (the glyco-
peptide teicoplanin) when applied intravenously (IV), 
each rescuing about half of the animals from severe 
pneumonia [2]. An ongoing challenge for phage therapy 
moving forward is the identification and exploitation of 
phage-antibiotic synergies [5]; however, in the rat VAP 
model, the IV phage-antibiotic combination did not syn-
ergize and still half of the animals treated with the com-
bination succumbed to the infection [2]. To determine 
if altering pharmacokinetic/pharmacodynamic (PK/PD) 
parameters could improve the efficacy of phage therapy, 
phages were nebulized and administered directly to the 
lungs of MRSA infected rats (‘aerophages’). Aerophages 
Open Access
BMC Research Notes
*Correspondence:  josef.prazak@insel.ch
1 Department of Intensive Care Medicine, Inselspital, Bern University 
Hospital, University of Bern, 3010 Bern, Switzerland
Full list of author information is available at the end of the article
Page 2 of 4Valente et al. BMC Res Notes          (2021) 14:381 
were as effective as the IV phage treatment (50% sur-
vival), and the combination of locally administered 
aerophages and systemically administered IV phages syn-
ergized to significantly improve animal survival (> 90%) 
and reduce lung bacterial burdens when compared to 
either therapy alone [4]. We reasoned that the efficacy of 
aerophage monotherapy was limited once the bacterial 
infection disseminated, and that the combination therapy 
with systemic phages was most effective as it could com-
bat both the pneumonia and subsequent bacteraemia. 
Using this rational, replacing IV phages with the front-
line antibiotic for MRSA, linezolid, which is likely to be 
a more clinically acceptable approach, should be similarly 
effective. This, however, was not observed, and post-hoc 
analysis of the linezolid-phage combination revealed 
antagonisms in vitro, whereby linezolid (a bacteriostatic 
protein synthesis inhibitor) appeared to inhibit phage 
replication, which was mirrored in vivo [4].
Main text
Rationale
In the current report, we tested the combinatorial effects 
of systemic daptomycin and aerophages for the treatment 
of experimental pneumonia due to MRSA. Daptomycin 
was chosen for three reasons. First, it is a bactericidal 
lipopeptide antibiotic that disrupts the bacterial cell 
membrane [6], thus it has a mode of action that is dis-
tinct from the other antibiotics that have been tested in 
combination with phages in this model (glycopeptides, 
oxazolidinone) [2, 4]. Secondly, the daptomycin-phage 
combination revealed neither synergisms nor antago-
nisms in vitro, as determined using checkerboard assays 
(methods described in [2], and finally, daptomycin is not 
recommended for use for bronchial–alveolar pneumo-
nia as its antibacterial effects are mitigated in the lung 
by surfactant, yet it has shown efficacy in the context of 
hematogenous pneumonia [7]. The final two points are of 
particular importance as they allow us to test the hypoth-
esis that a localised aerophage therapy can be improved 
in combination with systemic antibiotics; we do not 
expect improved efficacy due to classical phage-antibiotic 
synergy, rather the antibiotic effects should be limited to 
combating bacteria that have spread to sites other than 
the lung.
Material and methods
Experiments were performed according to the Com-
mittee on Animal Experiments of the Canton of Bern, 
Switzerland approval BE83/17 and according to ARRIVE 
Guidelines. Detailed methods about the model were 
published previously [2–4]. Briefly, a total number of 14 
male Wistar rats (Crl:WI(Han), 9–10 weeks old, Charles 
River, Germany) were ventilated for 4 h (10 mL/kg tidal 
volume, 5  cm  H2O positive end-expiratory pressure, 
50 breaths per minute with  FiO2 0.35) prior to inocula-
tion with alpha-toxin producing MRSA clinical strain 
AW7 (~  1010 colony forming units (CFU) per animal via 
the endotracheal tube) [8]. Animals were treated two 
hours after infection, and again at 12, 24, 48, and 72  h. 
Treatment was administered in an investigator/opera-
tor blinded manner and blinding was maintained until 
the end of data analysis. Animals were allocated ran-
domly (using GraphPad Prism, v7) to receive either IV 
daptomycin (6  mg/kg) and a nebulized placebo (filtered 
supernatant from the bacterial strain used for the phage 
propagation, n = 3 animals), or IV daptomycin and aer-
osolized phages (6  mg/kg daptomycin and ~ 2 ×  1010 
plaque forming units (PFU) of a nebulized cocktail of 
phage K, 3A, 2002 and 2003, n = 11 animals). This spe-
cific phage cocktail has been applied previously [2–4]. 
Phage K (Accession Number AY176327.1) and phage 3A 
(Accession Number NC_007053.1) were purchased from 
the University of Laval, Québec. Phage 2002 (Accession 
Number MW528836.1) was isolated from sewage water 
in Lausanne, Switzerland. Phage 2003 was isolated from 
the staphylococcal phage product of the Eliava Institute 
of Bacteriophages, Microbiology and Virology, Tbilissi, 
Georgia.
Based on our previous studies, the aerophage therapy 
alone results in 50% survival (Fig. 1A) [4]. We hypothe-
sized, that the combination of aerophage treatment with 
IV daptomycin would increase survival to 95–100%, sim-
ilar to the combination of IV phages with aerophages [4]. 
These estimates (alpha = 0.05, power 1−β = 0.8) required 
n = 11 per group (SigmaPlot 12.0). Animals were moni-
tored for 96  h, and illness was scored as described pre-
viously [2]. Animal survival at 96  h was the primary 
endpoint, and lung and spleen bacterial densities were 
determined following euthanasia as secondary end-
points. Animals scored as severely ill or reaching the 
primary endpoint at 96 h were euthanized as a humane 
endpoint using pentobarbital (150 mg/kg) injected intra-
peritoneally. Control groups (placebo treated, aerophage 
treated alone) were published in a previous study [4] and 
the data is included in the current study for comparison 
to reduce the number of animals required for experimen-
tation according to the 3R framework (Fig. 1A). Survival 
of animals was assessed using Kaplan–Meier curves and 
log-rank tests. All analyses were performed using Graph-
Pad Prism (v7).
Results
Three animals with pneumonia due to MRSA were 
treated with daptomycin IV plus nebulized placebo and 
each succumbed to infection within 12  h. The combi-
nation of daptomycin IV and aerophages rescued 55% 
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of animals from infection by the end of the 96-h trial 
(Fig.  1B). The combination, however, was not superior 
to aerophage therapy alone at improving animal survival 
(50%, Fig. 1B), or reducing bacterial burdens in the lungs, 
or spleen (which we use as a marker for systemic spread 
of infection) (Fig. 1C).
Discussion
It is likely, particularly in critical care situations, that 
phage therapy will be administered adjunct to antibiotics 
[5, 9]. The efficacy of phage therapy in animal models has 
now been tested extensively, however, only few studies 
have directly compared the efficacy of phages and anti-
biotics or assessed the efficacy of antibiotic-phage com-
binations in vivo. Worryingly, the same antibiotic-phage 
combination can show either synergisms or antagonisms 
depending on the concentration of each agent when 
tested in  vitro [10], and the efficacy of a given phage-
antibiotic combination can depend on the laboratory 
method used for assessment [2, 4, 10, 11]. Robust and 
standardized in vitro methods assessing phage-antibiotic 
synergies should be developed that can accurately predict 
improved treatment outcomes in  vivo. Additionally, 
in  vitro experiments have shown that staggered admin-
istration of phages and antibiotics (one, then the other, as 
opposed to each at the same time) may be more effective 
than antibiotics alone for the treatment of MRSA [11], 
and this warrants further investigation in a model such 
as that used in the current study. In conclusion, combi-
nation IV daptomycin and aerophages does not appear 
appropriate for use in patients with VAP, thus our search 
for in vivo phage-antibiotic synergy in MRSA pneumonia 
continues.
Limitations
As for most small animal models designed to mimic 
human infection, the model used in this study has some 
limitations. First, human VAP is defined as pneumonia 
occurring 48  h after the start of mechanical ventilation 
[12]. However, ventilation of rats over long time periods 
leads to extensive lung damage irrespective of infection 
and/or adequate treatment, limiting the time of ventila-
tion in the model to 4  h. Second, VAP is usually estab-
lished when a small inoculum of bacteria reaches the 
lower respiratory tract, where they adhere to the mucosa 
and start the infection [13]. In the current model, in order 
to establish reproducible pulmonary infection in immu-
nocompetent rats, a high bacterial load (~  1010 CFU per 
animal) had to be applied directly to the lungs via the 
endotracheal tube. Small reductions of the inoculum 
resulted in spontaneous clearance of the infection. As a 
consequence, the high inoculum led to severe infection 
whereby treatment needed to be administered quickly 
(2 h after infection) in order to avoid extensive mortality.
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Fig. 1 Combination IV daptomycin and aerophages in an 
experimental model of VAP due to MRSA. A Kaplan–Meier survival 
analysis for rats with pneumonia due to MRSA treated with either 
placebo (nebulized placebo and IV placebo, n = 8) or aerophages 
(~  1010 plaque forming units (PFU) of nebulized phage cocktail and 
IV placebo, n = 10), as reported in a previous study (4). B Kaplan–
Meier survival analysis for rats with pneumonia due to MRSA from 
the current study, treated with either IV daptomycin (6 mg/kg and 
nebulized placebo, n = 3) or IV daptomycin and aerophages (6 mg/
kg daptomycin IV, ~ 2 ×  1010 PFU of nebulized phage cocktail, n = 11). 
C Bacterial densities in the lungs of animals following euthanasia. D 
Bacterial densities in the spleen of animals following euthanasia. The 
dotted line represented the limit of detection. Dapto, daptomycin; 
CFU, colony forming unit
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